Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower all‐cause death median compared with placebo (high certainty).
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to lower 3P‐MACE median compared with placebo (moderate certainty).
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to lower 4P‐MACE median compared with placebo (moderate certainty).
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower kidney composite outcome median compared with placebo (high certainty).
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower kidney failure median compared with placebo (high certainty).
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower hypoglycaemia requiring third‐party assistance median compared with placebo (high certainty).
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to higher diabetic ketoacidosis median compared with placebo (moderate certainty).
The review found no eligible studies for this question.
wMel‐Wolbachia infected Aedes aegypti deployments probably leads to lower prevalence of DENV infection (any severity, any phenotype)a compared with no deployments (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Bupropion leads to higher smoking cessation (at least six months of compared with placebo/no pharmacological treatment (high certainty).
Bupropion showed no clear difference in serious adverse events compared with placebo/no pharmacological treatment (moderate certainty).
Bupropion leads to higher dropouts due to treatment compared with placebo/no pharmacological treatment (high certainty).
Bupropion plus nicotine replacement therapy (NRT) showed no clear difference in smoking cessation (at least six months of compared with NRT alone (low certainty).
Bupropion plus nicotine replacement therapy (NRT) showed no clear difference in serious adverse events compared with NRT alone (low certainty).
Bupropion plus nicotine replacement therapy (NRT) showed no clear difference in dropouts due to treatment compared with NRT alone (low certainty).